BRAF and colorectal carcinoma: <h4>Background</h4>While the triplet combination of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CET) yielded a higher response rate compared with the doublet combination of ENCO plus CET, no significant survival benefits of the triplet combination were observed in patients with <i>BRAF</i> V600E-mutant metastatic colorectal cancer (mCRC), according to the BEACON CRC study.